Leerink Partnrs Analysts Cut Earnings Estimates for IRWD

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Equities researchers at Leerink Partnrs dropped their Q1 2025 EPS estimates for Ironwood Pharmaceuticals in a note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst F. Khurshid now forecasts that the biotechnology company will post earnings per share of ($0.06) for the quarter, down from their previous estimate of $0.03. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.08 per share. Leerink Partnrs also issued estimates for Ironwood Pharmaceuticals’ Q2 2025 earnings at ($0.02) EPS and Q4 2025 earnings at $0.08 EPS.

A number of other research firms have also commented on IRWD. JMP Securities dropped their price target on shares of Ironwood Pharmaceuticals from $23.00 to $14.00 and set a “market outperform” rating on the stock in a research report on Thursday, January 30th. StockNews.com lowered shares of Ironwood Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, November 12th. Finally, Craig Hallum dropped their target price on shares of Ironwood Pharmaceuticals from $10.00 to $8.00 and set a “buy” rating on the stock in a research report on Wednesday, January 22nd. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.67.

Ironwood Pharmaceuticals Stock Up 3.8 %

NASDAQ:IRWD opened at $2.18 on Monday. Ironwood Pharmaceuticals has a 12 month low of $2.05 and a 12 month high of $15.70. The firm has a market cap of $348.87 million, a price-to-earnings ratio of -72.67 and a beta of 0.29. The company’s 50 day moving average is $3.83 and its 200-day moving average is $4.39.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.02 EPS for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.07). Ironwood Pharmaceuticals had a negative net margin of 0.65% and a negative return on equity of 0.96%. The firm had revenue of $91.60 million during the quarter, compared to the consensus estimate of $91.22 million. During the same period in the prior year, the business earned $0.12 EPS. The company’s revenue for the quarter was down 19.4% compared to the same quarter last year.

Institutional Investors Weigh In On Ironwood Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. KBC Group NV boosted its stake in shares of Ironwood Pharmaceuticals by 59.3% in the 3rd quarter. KBC Group NV now owns 8,593 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,198 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its stake in shares of Ironwood Pharmaceuticals by 10.4% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 33,932 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 3,209 shares in the last quarter. Creative Planning boosted its stake in shares of Ironwood Pharmaceuticals by 12.7% in the 3rd quarter. Creative Planning now owns 42,151 shares of the biotechnology company’s stock valued at $174,000 after purchasing an additional 4,749 shares in the last quarter. Quantinno Capital Management LP boosted its stake in shares of Ironwood Pharmaceuticals by 40.0% in the 3rd quarter. Quantinno Capital Management LP now owns 19,191 shares of the biotechnology company’s stock valued at $79,000 after purchasing an additional 5,482 shares in the last quarter. Finally, Everence Capital Management Inc. boosted its stake in shares of Ironwood Pharmaceuticals by 36.3% in the 3rd quarter. Everence Capital Management Inc. now owns 27,850 shares of the biotechnology company’s stock valued at $115,000 after purchasing an additional 7,420 shares in the last quarter.

Insider Buying and Selling

In other Ironwood Pharmaceuticals news, CFO Sravan Kumar Emany sold 11,001 shares of Ironwood Pharmaceuticals stock in a transaction on Monday, November 18th. The shares were sold at an average price of $4.08, for a total transaction of $44,884.08. Following the sale, the chief financial officer now owns 309,572 shares in the company, valued at $1,263,053.76. The trade was a 3.43 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 12.90% of the stock is currently owned by insiders.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc, a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries.